Vividion Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2013-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.vividion.com
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-10-16
- Lead Sponsor
- Vividion Therapeutics, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT06804824
- Locations
- 🇦🇺
Clinical Research South Australia (CRSA), Adelaide, South Australia, Australia
🇺🇸START Mid West, Grand Rapids, Michigan, United States
🇺🇸NEXT Austin, Austin, Texas, United States
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
- Conditions
- Advanced Solid TumorsAdvanced Hematologic Tumors
- Interventions
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2025-10-16
- Lead Sponsor
- Vividion Therapeutics, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT06188208
- Locations
- 🇺🇸
California Research Institute, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2025-10-21
- Lead Sponsor
- Vividion Therapeutics, Inc.
- Target Recruit Count
- 295
- Registration Number
- NCT06004245
- Locations
- 🇪🇸
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, BARCELONA, Spain
🇺🇸City of Hope Cancer Center, Duarte, California, United States
🇺🇸City of Hope - Santa Clarita, Valencia, California, United States
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2025-10-16
- Lead Sponsor
- Vividion Therapeutics, Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT05954312
- Locations
- 🇰🇷
National Cancer Center, Goyang, South Korea
🇰🇷Gachon University Gil Medical Center, Incheon, South Korea
🇰🇷Seoul National University; Bundang Hospital, Seongnam, South Korea